What's new

Clinical human trials begin for COVID-19 vaccine in China

Big congratulations to #PKU researcher Cao Yunlong, who's among @Nature's 10 people who helped shape science. Cao is on the list for “his rich characterizations of emerging variants,” which have “allowed researchers to keep step with SARS-CoV-2 as it evolves.” @yunlong_cao
Cao is a researcher at #PKU's Biomedical Pioneering Innovation Centre and a leading member of a research team led by PKU Prof. Xiaoliang Sunney Xie. Nature's 10 list 2022 explores “key developments in science”&“some of the people who played important parts in these milestones.”
 
.
. .
#Sinopharm's F61 nasal spray received clinical trial approval from Chinese national medical authority for people at high risk of exposure to the novel coronavirus. It will be an important weapon in the fight against the rapidly spreading #Omicron variant.
https://globaltimes.cn/page/202211/1280675.shtml
vip_3.png
发布于 福建​
来自 iPhone 11 Pro Max​
已编辑​
关注​
国药研发的F61单抗喷雾,开始上市销售了,对奥密克戎BA.5、BF.7有效​

Zheng Haorong
22-12-28 17:47 Posted in Fujian
From iPhone 11 Pro Max

The F61 monoclonal antibody spray developed by Sinopharm is now on the market and is effective for Omicron BA.5 and BF.7

1672289273889.png
 
.
A report on the therapeutic effect of China’s first COVID-19 oral drug VV116 was released Tuesday.

It concluded that confirmed patients receiving the drug within five days of their first positive test saw better treatment results. https://bit.ly/39wad4K
Interesting study showing an oral version of #remdesivir (VV16) works as well as #Paxlovid for reducing COVID symptoms (no severe illness or deaths in either group), but has fewer side effects. 1/
 
. . . . .
Pan-vaccine antigen strategy confers protection against cross-clade SARS-CoV-2 variants, including vaccine-resistant Omicron variants https://news-medical.net/news/20230106/Pan-vaccine-antigen-strategy-confers-protection-against-cross-clade-SARS-CoV-2-variants-including-vaccine-resistant-Omicron-variants.aspx…
“Our results highlight the importance and feasibility of a universal vaccine to fight against SARS-CoV-2 antigenic drift.”
@ScienceTM
 
. . .
Back
Top Bottom